Document is current
Any future updates will be listed below
-
Authors
Hunt, Kathryn https://orcid.org/0009-0007-6763-3952
Foran, Laura https://orcid.org/0009-0000-7188-012X
Malfitano, Carmine https://orcid.org/0000-0002-9561-9599
Rydall, Anne https://orcid.org/0000-0002-4692-9101
Nanos, Stephanie https://orcid.org/0009-0009-5437-831X
Malakian, Argin https://orcid.org/0000-0003-1322-1294
Schimmer, Aaron D. https://orcid.org/0000-0003-4023-3899
Nissim, Rinat https://orcid.org/0000-0002-3624-5806
Brennan, David https://orcid.org/0000-0002-7663-9869
Hannon, Breffni https://orcid.org/0000-0002-0881-555X
Zimmermann, Camilla https://orcid.org/0000-0003-4889-0244
Rodin, Gary https://orcid.org/0000-0002-6626-6974
-
Funding
Funding for this research was provided by:
Canadian Cancer Society (CCS QOL Grant #705398)
Canadian Institutes of Health Research (CIHR Project Grant #PJT-65483)
- License Information
-
More Information
Article History
Received: 9 July 2025
Accepted: 27 October 2025
First Online: 15 November 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. The University Health Network (UHN) Research Ethics Board (REB) approved the qualitative study on December 1, 2021 (CAPCR ID 21–5704), as an embedded component of the multi-site EASE RCT, which was approved by the Ontario Cancer Research Ethics Board (CTO Project ID 2103) and by the UHN REB (CAPCR ID 20–5425). All individual participants provided written informed consent to participate in the EASE RCT, and separate written informed consent for the qualitative interview.
: KH and LF each received 1.0 course credits towards completion of their Master of Social Work at the University of Toronto for their preliminary work on this project. ADS has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. ADS is named on a patent application for the use of DNT cells to treat AML. ADS is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada. All other authors declare no potential conflicts of interest.
: Preliminary findings from this study were presented by KH and LF at the 13th European Association of Palliative Care (EAPC) World Research Congress held in Barcelona, Spain, in May 2024, and as part of a symposium presented at the Canadian Association of Psychosocial Oncology (CAPO) 40th Annual Conference held in Toronto, Canada, in April 2025.
